Site icon pharmaceutical daily

Bronchopulmonary Dysplasia – Global Pipeline Review, H1 2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Bronchopulmonary
Dysplasia – Pipeline Review, H1 2019”
drug pipelines has been
added to ResearchAndMarkets.com’s offering.

Bronchopulmonary Dysplasia – Pipeline Review, H1 2019
provides comprehensive information on the therapeutics under development
for Bronchopulmonary Dysplasia (Respiratory), complete with analysis by
stage of development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type. The guide covers the descriptive
pharmacological action of the therapeutics, its complete research and
development history and latest news and press releases.

The Bronchopulmonary Dysplasia (Respiratory) pipeline guide also reviews
of key players involved in therapeutic development for Bronchopulmonary
Dysplasia and features dormant and discontinued projects. The guide
covers therapeutics under Development by
Companies/Universities/Institutes, the molecules developed by Companies
in Filing rejected/Withdrawn, Phase II, Phase I, IND/CTA Filed,
Preclinical and Discovery stages are 1, 3, 1, 1, 10 and 2 respectively.
Similarly, the Universities portfolio in Preclinical stages comprises 1
molecules, respectively.

Scope

Reasons to Buy

Companies Mentioned

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/42szui

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Respiratory
Drugs

Exit mobile version